First-, second-, third-line therapy for metastatic renal cell carcinoma (mRCC): Benchmarks for trials design from the International mRCC Database Consortium (IMDC)

被引：0
|
作者：
Heng, Daniel Yick Chin
Rini, Brian I.
Lee, Jae-Lyun
Kroeger, Nils
Srinivas, Sandy
Harshman, Lauren Christine
Knox, Jennifer J.
Bjarnason, Georg A.
MacKenzie, Mary J.
Wood, Lori
Vaishampayan, Ulka N.
Agarwal, Neeraj
Pal, Sumanta Kumar
Tan, Min-Han
Rha, Sun Young
Yuasa, Takeshi
Donskov, Frede
Bamias, Aristotelis
North, Scott A.
Choueiri, Toni K.
机构：
[1] Tom Baker Canc Clin, Calgary, AB, Canada
[2] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[4] Stanford Med Ctr, Stanford, CA USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Princess Margaret Canc Ctr, Toronto, ON, Canada
[7] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[8] London Reg Canc Program, London, ON, Canada
[9] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[10] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[11] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[12] City Hope Natl Med Ctr, Duarte, CA USA
[13] Inst Bioengn & Nanotechnol, Singapore, Singapore
[14] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[15] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[16] Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark
[17] Alexandra Peripheral Gen Hosp, Athens, Greece
[18] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4586
引用
收藏
页数：1
相关论文
共 50 条
  • [31] CLINICAL HETEROGENEITY AMONG FIRST-LINE SUNITINIB PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) CATEGORIZED AS INTERMEDIATE RISK (IR) GROUP ACCORDING TO THE INTERNATIONAL MRCC DATABASE CONSORTIUM (IMDC) RISK MODEL
    Huynh, L.
    Wells, J. C.
    Graham, J.
    Steinharter, J.
    McGregor, B.
    Donskov, F.
    Bjarnason, G. A.
    Vaishampayan, U.
    Hansen, A.
    Iafolla, M.
    Zanotti, G.
    Chang, R.
    Cheng, W. Y.
    Duh, M. S.
    Heng, D. Y. C.
    [J]. VALUE IN HEALTH, 2019, 22 : S59 - S60
  • [32] First-line (1L) immuno-oncology (10) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Dudani, Shaan
    Graham, Jeffrey
    Wells, Connor
    Pal, Sumanta K.
    Dizman, Nazli
    Donskov, Frede
    Bjarnason, Georg A.
    Hansen, Aaron Richard
    Iafolla, Marco Adelmo James
    Vaishampayan, Ulka N.
    Porta, Camillo
    Beuselinck, Benoit
    Yan, Flora
    Wood, Lori
    Liow, Elizabeth Chien Hern
    Kollmannsberger, Christian K.
    Yuasa, Takeshi
    Zhang, Chiyuan A.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [33] A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from a large international study
    Heng, D. Y.
    Xie, W.
    Bjarnason, G. A.
    Vaishampayan, U. N.
    Donskov, F.
    Wood, L.
    Knox, J. J.
    Tan, M.
    Kollmannsberger, C. K.
    Rini, B. I.
    Choueiri, T. K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] Outcome of metastatic sarcomatoid renal cell carcinoma (sRCC): Results from the International mRCC Database Consortium
    Chittoria, Namita
    Zhu, Hui
    Choueiri, Toni K.
    Kroeger, Nils
    Lee, Jae-Lyun
    Srinivas, Sandy
    Knox, Jennifer
    Bjarnason, Georg A.
    MacKenzie, Mary J.
    Wood, Lori
    Vaishamayan, Ulka N.
    Agarwal, Neeraj
    Pal, Sumanta Kumar
    Tan, Min-Han
    Rha, Sun Young
    Yuasa, Takeshi
    Donskov, Frede
    North, Scott A.
    Rini, Brian I.
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] The impact of impaired renal function on the effectiveness of first-line immuno-oncology combination therapies in metastatic renal cell carcinoma (mRCC): Results from the international metastatic RCC database consortium (IMDC)
    Navani, V.
    Ernst, M. S.
    Takemura, K.
    Pal, S. K.
    Powles, T. B.
    Donskov, F.
    Wells, J. C.
    Kollmannsberger, C. K.
    Beuselinck, B.
    Alva, A. S.
    Weickhardt, A. J.
    Lalani, A-K.
    Ernst, D. S.
    Agarwal, N.
    Choueiri, T. K.
    Heng, D. Y. C.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1215 - S1216
  • [36] Additional biological and clinical characteristics to refine International Metastatic RCC Database Consortium (IMDC) prognostic/predictive assessment in metastatic renal cell carcinoma (mRCC).
    Zampiva, Ilaria
    Merler, Sara
    Inzerilli, Nicola
    Zacchi, Francesca
    Manduca, Stefano
    Pafumi, Sarah
    Piacentini, Michela
    Marletta, Stefano
    Incani, Ursula Cesta
    Torroni, Lorena
    Vesentini, Roberta
    Marchetti, Pierpaolo
    Fantinel, Emanuela
    Zivi, Andrea
    Calio, Anna
    Brunelli, Matteo
    Verlato, Giuseppe
    Milella, Michele
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [37] Impact of bone and liver metastases (BM, LM) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs): Results from the International mRCC Database Consortium (IMDC)
    McKay, Rana R.
    Kroeger, Nils
    Xie, Wanling
    Lee, Jae-Lyun
    Knox, Jennifer J.
    Bjarnason, Georg A.
    MacKenzie, Mary J.
    Wood, Lori
    Srinivas, Sandy
    Vaishampayan, Ulka N.
    Rha, Sun Young
    Pal, Sumanta Kumar
    Donskov, Frede
    Tantravahi, Srinivas
    Rini, Brian I.
    Heng, Daniel Yick Chin
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [38] Change in International mRCC Database Consortium (IMDC) prognostic category and implications for efficacy of second-line targeted therapy.
    Davis, Ian D.
    Xie, Wanling
    Pezaro, Carmel Jo
    Donskov, Frede
    Wells, Connor
    Agarwal, Neeraj
    Srinivas, Sandhya
    Yuasa, Takeshi
    Beuselinck, Benoit
    Wood, Lori
    Ernst, D. Scott
    Kanesvaran, Ravindran
    Knox, Jennifer J.
    Pantuck, Allan J.
    Saleem, Sadia
    Alva, Ajjai Shivaram
    Rini, Brian I.
    Lee, Jae-Lyun
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [39] Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma (mRCC) treated with targeted therapy: Results from the International mRCC Database Consortium
    Xie, Wanling
    Choueiri, Toni K.
    Lee, Jae-Lyun
    Harshman, Lauren Christine
    Bjarnason, Georg A.
    Knox, Jennifer J.
    MacKenzie, Mary J.
    Wood, Lori
    Vaishampayan, Ulka N.
    Yuasa, Takeshi
    Tan, Min-Han
    Rha, Sun Young
    Donskov, Frede
    Agarwal, Neeraj
    Kollmannsberger, Christian K.
    North, Scott A.
    Rini, Brian I.
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] Real-world assessment of clinical outcomes among first-line (1L) sunitinib (SUN) patients (pts) with metastatic renal cell carcinoma (mRCC) by the international mRCC database consortium (IMDC) risk group.
    Savard, Marie-France
    Wells, J. Connor
    Graham, Jeffrey
    Steinharter, John A.
    McGregor, Bradley Alexander
    Donskov, Frede
    Bjarnason, Georg A.
    Vaishampayan, Ulka N.
    Hansen, Aaron Richard
    Iafolla, Marco Adelmo James
    Zanotti, Giovanni
    Huynh, Lynn
    Duh, Mei Sheng
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
12345